Navigation Links
BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
Date:8/20/2012

RALEIGH, N.C., Aug. 20, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that enrollment and the clinical portion of the pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence has been completed. 

(Logo:  http://photos.prnewswire.com/prnh/20110217/CL49801LOGO

As agreed with the U.S. Food and Drug Administration (FDA) in February 2012, the study, referred to as BNX-103, was designed to compare the relative bioavailability of buprenorphine and naloxone from BNX with the reference product Suboxone.  Meeting those requirements will represent a positive outcome of that study.  All subjects have been dosed and the analytical work (i.e., plasma sample analysis) is in process.  BDSI expects to report results from this pivotal pharmacokinetic study before the end of September.

The open-label safety study, which is the last clinical requirement for this program, is expected to complete by year-end.  Availability of the necessary product stability data for BNX in the first quarter of 2013 will be followed by submission of the NDA in the second quarter.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence.  BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo.  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYLTM is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release, the conference presentation described herein, and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, with respect to timing and prospects for the clinical development program for BEMA Buprenorphine/Naloxone) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
3. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
4. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
5. Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
6. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
7. Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
8. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
9. Casteel Schoenborn Names Wilson Grabill Of Counsel for Life Sciences Communications
10. Biodel to Present at 2012 Wedbush PacGrow Lifesciences Management Access Conference
11. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2020)... , ... August 28, 2020 , ... ... of primary care medical centers in Florida and San Antonio is happy to ... South Texas medical centers. , In this capacity he will serve as community ...
(Date:8/27/2020)... ... August 27, 2020 , ... Austin Oral Surgery – an ... to announce Dr. David Szalay, DDS, MD, has joined the practice. An accomplished oral ... new Pflugerville office, which is scheduled to open this fall. The new office is ...
(Date:8/27/2020)... FORT MYERS, Fla. (PRWEB) , ... August 27, 2020 , ... ... its Board of Directors. Dr. Friedman is an adult and pediatric neuro-oncologist who serves ... Duke University and as an educator at Duke University Medical School. , Internationally recognized, ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... ... Want to get moving, break up your routine, and make a difference right ... its fourth annual STEPtember campaign in the United States to raise funds and awareness ... at this moment — encouraging people to move in the ways that work for ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado State ... high-quality, career-relevant, and affordable online education – is proud to announce its new ... the first of its kind in the nation, the 60-credit hour program is ...
(Date:8/31/2020)... ... 2020 , ... The pandemic and topsy-turvy economic outlook continues to put financial strain on many ... to trim the fat from our monthly expenses and put more into savings, if possible. ... you have a financial safety net in place in case something were to happen to ...
(Date:8/31/2020)... ... ... In an effort to give back to the community in which it serves, ... with a special new rate code to benefit children and families at Ronald ... will be applied to any room type, any time, now through the end of ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, LLC, a venture-backed ... heart failure, today announced that the company has been awarded a Phase 1 ... National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). ...
Breaking Medicine News(10 mins):